Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STING Phase III trial of ICT-107 plus temozolomide in newly diagnosed glioblastoma
NL-OMON45749Phase 3Withdrawn
- Sponsor
- EOM Pharmaceutical Holdings, Inc.
- Start
- Apr 2016
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ict-107 in glioblastoma (GBM), sponsored by EOM Pharmaceutical Holdings, Inc. Planned start Apr 2016; status: withdrawn.
02
Drugs
ict-107
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON45749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45749.